title: Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: proteins interacting with the third cytoplasmic loop of dopamine D2 and D3 receptors.
abstract: Among the various dopamine receptors, D(2)-like receptors (D2R, D3R, and D4R) are characterized by a large third cytoplasmic loop, a short carboxyl-terminal tail, and the ability to activate inhibitory G proteins. The diverse activities of D(2)-like receptors are partly mediated by proteins that interact with the third cytoplasmic loop, which regulate receptor signaling, receptor trafficking, and stability. Furthermore, in the case of D2R and D3R genes, mRNA splicing generates isoforms in the region of the third cytoplasmic loop. The gene encoding D2R gives rise to two isoforms, termed the dopamine D(2) receptor long isoform (D2LR) and the dopamine D(2) receptor short isoform (D2SR), which lacks 29 amino acids of the D2LR within the third cytoplasmic loop. The D3R gene also produces at least seven distinct alternative splicing variants including D3nf, in which 98 base pairs in the carboxyl-terminal region of the third intracellular loop are deleted. In this review, we focus on proteins interacting with the dopamine D(2)/D(3) receptors in the third cytoplasmic loop. We also define a novel binding protein, heart-type fatty acid-binding protein (H-FABP), which specifically interacts with the 29 D2LR amino acids deleted in D2SR and document its function in D2LR signaling.
authors: Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan.
authors: Norifumi
authors: N
authors: Shioda
authors: Yusuke
authors: Y
authors: Takeuchi
authors: Kohji
authors: K
authors: Fukunaga
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D004298:Dopamine / Q000502:physiology; D055808:Drug Discovery / Q000379:methods*; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008969:Molecular Sequence Data; D011485:Protein Binding / Q000502:physiology; D025941:Protein Interaction Mapping / Q000379:methods*; D017448:Receptors, Dopamine D2 / Q000378:metabolism* / Q000502:physiology; D050637:Receptors, Dopamine D3 / Q000378:metabolism* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
chemical_list: C493408:FABP3 protein, human; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D004298:Dopamine